That overwhelming sleepiness dragging you down might not just be from staying up too late scrolling through TikTok. While everyone occasionally battles the afternoon slump, people with hypersomnia or ...

Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2). Narcolepsy type ...

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...

Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals and its sleep disorder pipeline.

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.

Undiagnosed sleep disorders are causing millions of Americans to struggle for years. A nonprofit is dedicated to spreading ...